Friday, March 18, 2022

Investor Ideas #Potcasts 628, #Cannabis News and #Stocks on the Move (OTC: $TPIA), (TSXV: $MUSH.V), (CSE: $TRUL.C) (OTCQX: $TCNNF)

 



Investor Ideas #Potcasts 628, #Cannabis News and #Stocks on the Move (OTC: $TPIA), (TSXV: $MUSH.V), (CSE: $TRUL.C) (OTCQX: $TCNNF)

 

Delta, Kelowna, BC, March 18, 2022 (Investorideas.com Newswire), investorideas.com,  a global news source covering leading sectors including marijuana and hemp stocks and its potcast site  release today’s podcast edition of  cannabis news and stocks to watch plus insight from thought leaders and experts.

 

Listen to the podcast:

https://www.investorideas.com/Audio/Podcasts/2022/031822-StocksToWatch.mp3

 

Read this in full at https://www.investorideas.com/news/2022/cannabis-potcasts/03181TPIA-MUSH-TRUL-TCNNF.asp

 

Hear Investor ideas cannabis potcast on iTunes  

 

Hear the investor ideas potcast on Spotify

 

Today’s podcast overview/transcript:

 

In today’s podcast we look at a few private and public company announcements.

 

Now everyone can contribute to world-changing scientific discoveries with the right tools and questions. Quantified Citizen is a mobile health research platform that powers scientific discovery through digitized health measures and a community of professional researchers and citizen scientists.

 

The app leverages standard health measures that make it easy for anyone to rapidly create and deploy behavioral research studies. It has a growing library of studies on interventions like psychedelic microdosing for mental health, conditions like sobriety and its connections to mood, creativity, productivity and more. Anyone can choose studies based on their interests and, in as little as two minutes a day, contribute to global health and science.

 

"We envision a world where doing scientifically valid health research is as fast and easy as creating a website, with the same global reach. Where scientific tinkering and self-examination are normalized, vastly accelerating the pace of discovery by unlocking unexamined data," shares co-founder and CEO Eesmyal Santos-Brault.

 

Quantified Citizen's study on psychedelic microdosing's effects on cognitive performance and mental health was recently published in the prestigious Nature Scientific Reports. The study, informally called Microdose.me, is the largest microdosing study in the world at 17,000 participants and counting, and has been presented at numerous conferences, including Exponential Medicine, SXSW, Summit LA, and soon TED and Life Itself.

 

"For way too long, science has been the domain of a professional class, and citizens have been merely passive observers. By partnering with citizen scientists, we aim to empower a generation of amateur researchers, and unlock scientific curiosity, imagination, and creativity on a scale never seen before," says co-founder and CTO Kalin Harvey

 

The Quantified Citizen app is available on iOS and Android. A recent update offers visual redesign, new tasks and activities, and the ability to connect Apple Health or Google Fit.

 

New studies have also been announced:

      Impact of COVID-19 - Exploring the impact of the COVID-19 pandemic on various aspects of mental health and social relationships.

      Mental Health Tracker - Does mental health fluctuate with the seasons? Is it affected by a new routine or treatment regimen like a new medication?

      Attitudes Towards Psychedelics - A global survey of attitudes and beliefs towards psychedelics.

      Sobriety and Well-being Study - How abstaining from alcohol or cannabis for one month affects sleep.

      Personality and Drug Use - Do drugs play a role in altering our personalities?

 

To fuel further growth and development of new study capabilities, Quantified Citizen is pleased to announce the closing of its oversubscribed Series Seed financing round, led by Bicycle Day Ventures and Limitless, along with notable investors Paul Stamets, Lance Tracey, Iter Investments, and Empath Ventures.

 

Mycotopia Therapies Inc. (OTC: TPIA), a biopharma company focused on research, technology, and the development of medical psychedelics, announced plans to expand its supply agreement with Havn Life Sciences (CSE: HAVN) (OTC: HAVLF) to include functional mushrooms, which refers specifically to varieties of mushrooms that have a health benefit beyond providing nutrition. The terms of the original agreement call for Havn Life Sciences to supply Mycotopia Therapies with naturally-derived psilocybin. Under the terms of the agreement, Mycotopia Therapies is classified as a specialty pharmaceutical company focused on the research, development, and commercialization of novel therapeutics for unmet needs.

 

Under the terms of the existing agreement, Mycotopia Therapies is building a distribution channel to supply naturally-derived psilocybin compounds, in accordance with all federal laws and local protocols, to universities, researchers and companies. The expanded agreement Mycotopia Therapies provides Mycotopia Therapies with the opportunity to distribute functional mushrooms, as well as the white label supply and distribution of HAVN’s line of natural OTC health products currently being registered with the Jamaican Ministry of Health (MOH). Jamaica’s Ministry of Health is the pre-eminent Government organization whose mandate is “To ensure the provision of quality health services and to promote healthy lifestyles and environmental practices.” The Ministry, together with its Regional Health Authorities, Agencies and related organizations make up the public health system and are responsible for health care delivery across the island.

 

In December 2021 Mycotopia Therapies Inc. announced it had entered into a letter of intent regarding a potential acquisition of botanical psilocybin pioneer, Ei.Ventures. When a definitive agreement is reached, the combined companies intend to pool their resources to develop regulatory approved, plant-derived, psychoactive therapeutic treatment options and non-psychoactive nutritional supplements and related products that address global mental healthcare needs. Upon closing, the company would be renamed PSLY.com to better reflect the Company’s business moving forward.

 

Mycotopia Therapies is focused on the research, development, and commercialization of novel therapeutics based on naturally-derived psilocybin. Performing most of its research in Jamaica, where psilocybin is legal, Mycotopia Therapies is focused on mushroom and psychedelic opportunities. Ei.Ventures’ flagship botanical psilocybin-based formulation Psilly is a whole-plant botanical psilocybin-based formulation, which is currently in the pre-clinical phase. The goal of the combined companies would be to complete pre-clinical and phase 1 trials and launch therapeutic Psilly into jurisdictions where psilocybin is legal. Ei.Ventures has pioneered using the whole plant and fungi in its botanical formulations, which has the potential to create the “Entourage Effect.” Researchers suggest the Entourage Effect could be key to Psilocybin’s healing properties. The Entourage Effect is a synergistic interaction between two or more different molecules found within the same plant, which is similar to the effects various strains of cannabis has on the end-user.

 

Ben Kaplan, CEO of Mycotopia Therapies said, "Mushrooms were the second highest growing natural health supplement and are underserviced in the market. This partnership helps support our company's ambitious product development and R&D milestones by offering a potential alternative to synthetic derived psilocybin at a fraction of the cost.” Mr. Kaplan continued, “Since Havn Life Sciences will supply Mycotopia Therapies with functional mushroom, it helps addresses potential supply chain issues and enables Mycotopia Therapies to get to the distribution and revenue generation phase of our business plan, as we join forces with eI.ventures and form PSLY.com."

 

The Good Shroom Co Inc. (TSXV: MUSH), provides an update on sales and distribution.

 

MUSH, through its licensed subsidiary Teonan Biomedical Inc. (the "Subsidiary"), operates 2 cannabis brands; Nordique Royale™ and Velada™representing functional cannabis beverages and popular hash extracts. December 24, 2021 marked the launch of Nordique Royale's Afghan Gold hashish in Quebec. According to https://quebec.weedcrawler.ca/best_sellers, three weeks later the product was ranked #4 in sales in its category out of approximately 35 hash products.  During that same period hash sales for the Company were just over $250K and are expected to continue for the immediate term.

The first week of February 2022 marked the launch of the first two Velada™ cannabis beverages in Ontario. According to the Ontario Cannabis Store, for its first week of sales Velada™ products ranked #1 and #2 in its category, representing $27,480 in sales.

For both Nordique Royale™ and Velada™ sales quickly surpassed expectations and inventory was depleted much quicker than anticipated which led to a temporary drop in sales.  At present, all cannabis products have been restocked or are in process of being completed in line with revised projections to ensure MUSH minimizes any disruptions in inventory going forward.

 

MUSH also expects to launch 2 Velada cannabis beverages in every single Quebec cannabis store the week of February 21, 2022. At present in Quebec Velada cannabis beverages are only sold online. According to the government of Quebec online sales account for approximately 10% of total sales in the province. Despite only being sold online, according to quebec.weed crawler.ca, 3 Velada beverages are in the top selling products in its category even when ranked against products sold in stores.

 

MUSH, through the Subsidiary, also operates Teonan™ functional mushroom beverages.  These beverages have been accepted by two of the largest consumer packaged goods distributors in the United States, KEHE Food Distributors Inc. ("Kehe") and United Natural Foods Inc. ("UNFI").  As a result, Teonan™ is now distributed out of several locations and available to all retailers in the US. Though just initiated recently, the Subsidiary has already received 4 purchase orders which include two large accounts and a variety of small accounts. MUSH sales force led by FDM Sales management has now begun fulfilling orders and submitting products for review with its large retail accounts.

 

 

GreenBroz Inc., known as an industry-disruptive innovator of post-harvest processing technology for the cannabis industry, today officially announced the release of their Model G Precision Grinder + Destemmer. Featuring a first-of-its-kind continuous throughput system, the Model G is the first combination destemmer and grinder on the market.

 

Removing stems from milled flower efficiently while maintaining product quality and controlling particle size have been substantial obstacles for operators to overcome.

 

"It is a significant milestone for us to be able to deliver this technology that solves the long-standing problem of creating uniform particulates for the pre-roll, concentrates and edibles segments while maintaining a high degree of quality, efficiency and throughput," said Cullen Raichart, Founder and CEO of GreenBroz Inc. "Five years of concentrated work by our engineering team and countless hours of testing has produced what we are confident is an enduring solution."

 

The R&D team's key innovation is the Model G's patent-pending triangular blade assembly. When combined with the low torque, low-RPM motor it allows for a high degree of control over particle size while its gentle actuation generates less heat, maintaining the integrity of high-value terpenes and trichomes, maximizing THC content per pound.

 

"Unlike other machines on the market today that pulverize buds, the Model G was designed to gently deconstruct the bud to yield the uniform grind size of your choice," said GreenBroz Engineer Dylan Cruz. The Model G comes with 1/8-inch, 5/32-inch or 3/16-inch mill size interchangeable screens, giving customers control and flexibility. The unit can be completely customized by adding a stainless steel perforated metal sheet of any size.

 

Engineered to be gentle and efficient, the Model G is made in the U.S. at the GreenBroz Las Vegas manufacturing facility and can process over 100 pounds per hour.

 

Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF), a leading and top-performing cannabis company in the United States, launched its nationwide Supplier Diversity Initiative. The initiative provides education and professional development resources, while creating mutually beneficial business relationships with a supplier base reflective of the customers and communities Trulieve serves.

 

Suppliers nationwide are encouraged to register with Trulieve's supplier database. Through the Company's comprehensive Supplier Diversity Initiative, Trulieve will consider all varieties of products and services from marketing and software, to cleaning supplies, training, construction and other ancillary services that support Trulieve's day-to-day operations.

 

"Trulieve's Supplier Diversity Initiative showcases how cannabis leaders can positively impact local business communities while promoting diversity, equity, and inclusion throughout the cannabis industry," said Kim Rivers, CEO of Trulieve. "As Trulieve broadens its services and operations, we look forward to establishing new professional relationships with diverse business owners who wish to be active participants in this rapidly growing sector."

 

As corporate members of the National Minority Supplier Development Council, Women's Business Enterprise National Council, Small Business Administration, Veterans in Business Network, National Gay & Lesbian Chamber of Commerce, and Disability Inclusion, Trulieve is actively seeking partnerships with diverse suppliers by participating with these certifying organizations and attending council events.

 

In November 2021, Trulieve published its inaugural Environment, Social, and Governance (ESG) Report establishing several long-term Diversity, Equity, and Inclusion (DEI) initiatives. The Supplier Diversity Initiative is the latest extension of Trulieve's commitment to creating a more inclusive and accessible cannabis industry aligned with the Company's ethics and governance standards. Since entering Georgia, Trulieve has already allocated a significant portion of its supplier contracts to local minority, woman and veteran-owned companies – well above the state's recommended 20% diversity threshold.

 

Investor ideas reminds all listeners to read our disclaimers and disclosures on the Investorideas.com website and that this podcast is not an endorsement to buy products or services or securities. Investors are reminded all investment involves risk and possible loss of investment.

To hear more Investorideas.com podcasts visit: https://www.investorideas.com/Audio/.

The Investorideas.com podcasts are also available on iTunes ( Apple Podcasts) ,  Audible , Spotify, Tunein, Stitcher, Spreaker.com, iHeartRadio ,  Google Podcasts and most audio platforms available.

 

About Investorideas.com - News that Inspires Big Investing Ideas

Investorideas.com publishes breaking stock news, third party stock research , guest posts and original  articles and podcasts in leading stock sectors.  Learn about investing in stocks and get  investor ideas in cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy, gaming and more. Investor Idea’s original branded content includes podcasts and columns : Crypto Corner , Play by Play sports and stock news , Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast ,  Cleantech and Climate Change , Exploring Mining , Betting on Gaming Stocks Podcast and  the AI Eye Podcast.     

 

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

 

Investor Ideas does not condone the use of cannabis except where permissible by law. Our site does not possess, distribute, or sell cannabis products.

No comments:

Post a Comment